

Scientific Program

Wednesday, March 1, 1995

09.30–17.30	Registration (all day, OLMA Conference Centre, Hall 2)
11.00–12.30	Meet the Expert Luncheon Taxol®: A New Adjuvant Therapy of Breast Cancer? (organized by Bristol-Myers Squibb) Moderator: A Goldhirsch, Lugano, Switzerland
13.30–15.00	Satellite Workshop A The Role of Anthracyclines in Early Stage II Breast Cancer (organized by Pharmacia) Moderators: G Bonadonna, Milan, Italy; HJ Senn, St. Gallen, Switzerland

15.30	Welcome Address HJ Senn, St. Gallen, Switzerland
15.40	Opening Address The Changing Concept in Treating Breast Cancer, 1995 U Veronesi, Milan, Italy
16.00–17.30	Session 1. Epidemiology and Genetics of Breast Cancer Chairman and Discussant: M Tattersall, Sydney, Australia
16.00	S1 Inherited Breast Cancers BL Weber, Ann Arbor, USA
16.20	S2 Breast Cancer Epidemics: Genetic and Environmental Aspects EJ Sondik, Bethesda, USA
16.40	S3 A Review of Nutritional Aspects of Mammary Gland Cancer EG Snyderwine, Bethesda, USA
17.00	S4 Timing of Breast Cancer Surgery and Metastatic Potential WJM Hrushesky, Albany, USA
17.15	Discussion and Summary
17.45	Adjourn: Buses leave OLMA Centre for downtown Buffet Reception at the 'Zeughausflügel' of the Government Building (Klosterplatz)

19.30–20.30	Opening Concert In St. Laurenzen Church (adjacent to the Buffet Reception) The Dorian Consort, St.Gallen: works by JS Bach and A Vivaldi Buses leave for out-of-town hotels 30 minutes after the concert
-------------	--

Thursday, March 2, 1995, a.m.

09.00–10.30	Session 2. Biology of Breast Cancer Chairman and Discussant: A Harris, Oxford, UK
09.00	S5 Growth Factors and Breast Cancer: Transformation, Proliferation and Metastases M Pollak, Montreal, Canada
09.20	S6 Transferring Growth Factor Research into Clinics CB Siegall, Seattle, USA
09.40	S7 Tamoxifen and Endometrial Cancer: From Experiment to Patient VC Jordan, Chicago, USA
10.00	Discussion and Summary

10.30–11.00 Coffee Break, Poster Session I, Industrial Exhibition

11.00	Session 3. Prognosis of Response and Tumor Markers Chairman and Discussant: M Baum, London, UK
11.00	S8 Review of Known Prognostic Variables M Kaufmann, Heidelberg, Germany
11.20	S9 Prognostic Variables and Future Predictors of Response B Gusterson, London, UK
11.40	S10 Serum Tumor Markers for Breast Cancer DF Hayes, Boston, USA
12.00	Discussion and Summary

12.30–14.00 Lunch, Posters I, Industrial Exhibition

Thursday, March 2, 1995, p.m.

14.00–15.30 Session 4. Screening for Breast Cancer and Treatment of Early Lesions (DCIS)

Chairman and Discussant: J Forbes, Newcastle, Australia

14.00 S11 A Critical Review of Screening for Breast Cancer

M Rosselli del Turco, Florence, Italy

14.20 S12 The Treatment of DCIS from the Point of View of the Surgeon

RG Margoese, Montreal, Canada

14.40 S13 Predicting Patients Likely to Recur after Conservative Treatment for DCIS

MJ Silverstein, Van Nuys, CA, USA

15.00 Discussion and Summary

15.30–16.00 Coffee Break, Posters I, Industrial Exhibition

16.00–17.30 Session 5. Surgery for Breast Cancer: Special Issues

Chairman and Discussant: W Wood, Atlanta, USA

16.00 S15 The American Breast Cancer Tragedy: Its Impact on NSABP Clinical Trials

B Fisher, Pittsburgh, USA

16.20 S16 The Surgical Treatment Approach of Breast Cancer Relapse

R Margoese, Montreal, Canada

16.40 S17 Primary and Secondary Breast Reconstruction with Special Emphasis on the Use of Prosthesis

J-Y Petit, Milan, Italy

17.00 Discussion and Summary

17.30 Adjourn

18.00–19.30 Satellite Workshop B

Filgrastim: Dose Concepts in the Treatment of Breast Cancer in the Adjuvant and Metastatic Setting

(organized by Amgen Roche; see special program)

Moderator: F Cavalli, Bellinzona, Switzerland

Friday, March 3, 1995, a.m.

09.00–10.30 Session 6. Adjuvant Systemic Therapy I

Chairman and Discussant: IC Henderson, San Francisco, USA

**09.00 S18 The Primary Use of Chemotherapy for Operable Breast Cancer:
Does Systemic Therapy Make Surgery Superfluous?**

C-M Rudenstam, Gothenburg, Sweden

**09.20 S19 High Dose Chemotherapy as Adjuvant Therapy for Breast Cancer:
Where Do We Stand?**

W Peters, Durham, USA

**09.40 S20 The Role of Anthracyclines in Adjuvant Chemotherapy of Breast Cancer:
A Critical Appraisal**

H Mouridsen, Copenhagen, Denmark

10.00 Discussion and Summary

10.30–11.00 Coffee Break, Posters II, Industrial Exhibition

11.00–12.30 Session 7. Adjuvant Systemic Therapy II

Chairman and Discussant: B Fisher, Pittsburgh, USA

11.00 S21 Adjuvant Systemic Therapy: The Issue of Timing and Sequence

M Castiglione, Bern, Switzerland

**11.20 S22 Current Role of Adjuvant Hormone Therapy in the Management of Early Carcinoma
of the Breast**

M Baum, London, UK

11.40 S23 Future Developments in Adjuvant Systemic Therapy of Breast Cancer

G Bonadonna, Milan, Italy

12.00 Discussion and Summary

12.30–14.00 Lunch, Posters II, Industrial Exhibition

Friday, March 3, 1995, p.m.

14.00–16.30 Session 8. Radiation Therapy as Part of Primary Treatment

Chairman and Discussant: A Goldhirsch, Lugano, Switzerland

14.00 S24 Radiation Therapies for Breast Cancer: Current Knowledge of Advantages and Disadvantages

L Rutqvist, Stockholm, Sweden

14.20 S25 Quality Assurance in Early Breast Cancer Post-Operative External Whole-Breast Irradiation: Clinical Aspects

R Valdagni, Milan, Italy

14.40 S26 How to Predict Relapses after Breast-Conserving Treatment

JM Kurtz, Geneva, Switzerland

15.00 Discussion and Summary

A Goldhirsch

15.30–16.00 Coffee Break, Posters II, Industrial Exhibition

16.00–17.30 Session 9. Women's Health Perception and Breast Cancer: Issues of Fertility, Hormone Substitution and Cancer Prevention

Chairperson and Discussant: KI Pritchard, Toronto, Canada

16.00 S27 Reproductive Potential after Adjuvant Chemotherapy for Breast Cancer

P Valagussa, Milan, Italy

16.15 S28 Sex Hormones and Breast Cancer: The Issue of Hormone Replacement

KI Pritchard, Toronto, Canada

16.30 S29 The Women's Health Initiative: The Road to Scientific Clarity?

WC Willett, Boston, USA

16.45 S30 Breast Cancer Prevention: Problems of Current Trials

C Redmond, Pittsburgh, USA

17.00 Discussion and Summary

17.30 Adjourn: Buses leave at 17.45 for Buffet Dinner at City Theatre (18.00)

19.30 Opera Performance

'I Lombardi', by Giuseppe Verdi, St. Gallen City Theatre

(free of charge, pre-registration necessary for tickets)

Buses leave for out-of-town hotels 30 minutes after the performance

Saturday, March 4, 1995, a.m.

09.00–12.15	Session 10. International Consensus Conference on Primary Treatment of Breast Cancer Chairmen: JH Glick, Philadelphia, USA; A Goldhirsch, Lugano, Switzerland
09.00	Part 1. Topics New Prognostic Factors, Role of Tumor Markers Treatment of Screening-Detected Breast Cancer and DCIS Treatment of the Elderly High Dose Chemotherapy for Adjuvant Disease
10.30–11.00	Coffee Break, Industrial Exhibition
11.00	Part 2. Topics 'Standard' Regimens for Patients Outside of Clinical Trials? Informed Consent for Patients Outside of Clinical Trials? Any other matter, as desired by the audience Panel Discussants: K Antman, New York, USA M Baum, London, UK G Bonadonna, Milan, Italy J Forbes, Newcastle, Australia B Fisher, Pittsburgh, USA R Gelber, Boston, USA CI Henderson, San Francisco, USA M Kaufmann, Heidelberg, Germany JM Kurtz, Geneva, Switzerland H Mouridsen, Copenhagen, Denmark KI Pritchard, Toronto, Canada C-M Rudenstam, Gothenburg, Sweden
12.15	Closing Remarks HJ Senn
12.20	End of the Conference
12.45	Departure (from Conference Centre) for Appenzell Mountain Tour, for participants holding tickets (see Tourist Office)
14.30	IBCSG Scientific Committee and Council Meetings Hotel 'Säntispark', Abtwil, St. Gallen (by invitation only)
20.00	Start of IBCSG Plenary Meeting Hotel 'Säntispark', Abtwil, St. Gallen, with Opening Dinner (for members, by invitation only)